Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials

Keyphrases

• Clinical Trials 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Cancer Therapeutics 100%
• Lung Cancer 30%
• Poor Performance Status 20%
• Patient Refusal 20%
• Histology 10%
• Comorbid Conditions 10%
• United States 10%
• Performance Status 10%
• Disease Diagnosis 10%
• Consecutive Patients 10%
• Cancer Mortality 10%
• Recent Advances 10%
• Medical Center 10%
• Cancer Center 10%
• Histological Subtypes 10%
• Small Fraction 10%
• Cancer Causes 10%
• Medical Oncology 10%
• Disease Stage 10%
• Therapeutic Management 10%
• Insurance Status 10%
• Stage Performance 10%
• Non-participation 10%
• Lung Cancer Clinical Trials 10%
• Barriers to Participation 10%
• Ineligibility 10%
• Insurance Issues 10%
• Non-enrolment 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Non Small Cell Lung Cancer 100%
• Lung Cancer 36%
• Malignant Neoplasm 18%
• Diseases 9%